Hypopigmentation

Journal of Pharmaceutical Analysis (JPA) Studies Find Promising Drug Candidates

Retrieved on: 
Friday, March 29, 2024
Hydralazine, Issue 1, DHT, Pigment, UBA52, Neuroregeneration, Prevalence, Apoptosis, PNI, Serum, Homeostasis, Patient, Ferroptosis, JPA, Neuron, HYD, Metformin, Type, Nerve, BPH, Hypopigmentation, EB, Depigmentation, Met, Oxidative stress, Iron, Pharmaceutical industry

XI'AN, China, March 29, 2024 /PRNewswire/ -- Understanding the underlying mechanisms of normal and pathological cellular processes is essential for developing new drugs. Fortunately, modern techniques and experimental methods have greatly accelerated progress. The latest issue of JPA features three articles in which candidate compounds for treating complex disorders were successfully identified, alongside their detailed mechanisms of action.

Key Points: 
  • The first study investigated the use of metformin (Met), a drug used to manage type II diabetes, for treating benign prostate hyperplasia (BPH).
  • The article was published in Volume 14, Issue 1 of the journal in January 2024 .
  • Using the Drug Signatures Database, they identified hydralazine (HYD), a potent arterial vasodilator, as a potential UBA52 disruptor.
  • Further studies will hopefully clarify the intricate connections among cellular processes, diseases, and potential drugs, paving the way for precise and efficient therapies.

PNU Researchers Reveal Cutibacterium acnes as a Potential Cause of Lichen Striatus Hypopigmentation

Retrieved on: 
Wednesday, January 17, 2024
Patient, Research, Associate, Professor, Skin, Whole genome sequencing, Acne, Comamonas, Pusan National University, Quality of life, Bacteria, Blaschko's lines, Journal, Observation, Microbiota, Health informatics, Biopsy, Hypopigmentation, Antifungal, Sulfur

The gram-positive bacterium Cutibacterium acnes has previously been associated with various skin conditions, including acne vulgaris and post-inflammatory hypopigmentation.

Key Points: 
  • The gram-positive bacterium Cutibacterium acnes has previously been associated with various skin conditions, including acne vulgaris and post-inflammatory hypopigmentation.
  • There could, therefore, be a potential association between C. acnes and the observed skin microbiota of patients with LS with and without hypopigmentation.
  • Comparing patients with LS with and without hypopigmentation, the researchers discovered a quadrupled presence (23.26% versus 5.29% of the entire microbiota) of Cutibacterium acnes in the former.
  • Title of original paper: Association between the skin microbiome and lichen striatus hypopigmentation: Cutibacterium acnes as a potential cause

Latest study demonstrates high efficacy in curing invasive non-melanoma skin cancer

Retrieved on: 
Wednesday, October 25, 2023
Neoplasm, Patient, Cutaneous squamous-cell carcinoma, Incidence, NMSC, Georgetown University Medical Center, BCC, University Medical Center, Head, Face, Basal-cell carcinoma, CSCC, Cryotherapy, Carcinoma, Cancer, Radiation, Ear, Rhenium, Safety, Skin cancer, Hypopigmentation, Nose, Dentistry, Pharmaceutical industry, Veterinary medicine

MUNICH, Oct. 25, 2023 /PRNewswire/ -- Results from a recently completed study show topical rhenium-188 skin cancer therapy to be a highly effective option for treating non-melanoma skin cancer (NMSC) of up to 3 mm thickness.1

Key Points: 
  • Research lead, Professor Tietze from the University Medical Center, Rostock says, "The study found rhenium skin cancer therapy to be a highly effective treatment for NMSCs, in particular, the cosmetic outcomes on the head and face.
  • The study involved 22 patients with 40 histologically confirmed NMSCs (57.5% basal cell carcinomas (BCCs), 12.5% cutaneous squamous cell carcinomas (cSCCs), 30% Bowen's disease lesions).
  • This study shows the efficacy of rhenium skin cancer therapy demonstrating a 97.5% response rate with 37 of the 39 lesions showing complete response at 12 months," adds Professor Tietze.
  • All procedures performed in this study were in accordance with the 1964 Helsinki declaration and its later amendments.

DermBiont Presents Positive Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel at American Academy of Dermatology Annual Meeting

Retrieved on: 
Wednesday, March 22, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, American Academy of Dermatology, Hypopigmentation, Therapy, SKS, Cryosurgery, Neoplasm, Food, Edema, Clinical trial, Scar, American Academy, Itch, Pain, Erythema, Patient, AKT, AAD, Risk, BID, Apoptosis, Hyperpigmentation, PLA, Entrepreneurship, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Skin, Safety, Casting, Pharmaceutical industry, Wood-plastic composite

SM-020 is a selective and potent AKT inhibitor applied by patients at home to their seborrheic keratoses (SK) lesions.

Key Points: 
  • SM-020 is a selective and potent AKT inhibitor applied by patients at home to their seborrheic keratoses (SK) lesions.
  • SKs are currently treated with ablative surgical procedures and there is currently no available topical therapy for these tumors.
  • DermBiont’s Phase 2 proof-of-concept, adaptive open-label trial tested SM-020 gel 0.1% and 1.0%, enrolling 35 subjects with 4 SK target lesions across seven treatment cohorts.
  • "We are pleased to have presented positive results from our Phase 2 adaptive, open-label trial with SM-020 at the prominent AAD annual meeting.

Local Tattoo Removal Salon Introduces Patent Pending Method That is Raising the Standard for Treatment Outcomes

Retrieved on: 
Friday, March 18, 2022
Ink, Life, Tattoo, White, Heat, Skin, Laser, Common, Burns, Deletion, Hyperpigmentation, Harris Interactive, Scar, Ipsos, Hypopigmentation, Patient, Mineral oil, Phoenix

PHOENIX, March 18, 2022 /PRNewswire-PRWeb/ -- Delete Tattoo Removal & Medical Salon, a Valley business serving patients for more than 11 years, has introduced a new, highly-effective patent pending tattoo removal process called the Delete Method.

Key Points: 
  • PHOENIX, March 18, 2022 /PRNewswire-PRWeb/ -- Delete Tattoo Removal & Medical Salon, a Valley business serving patients for more than 11 years, has introduced a new, highly-effective patent pending tattoo removal process called the Delete Method.
  • "A common reason why many tattoo removal treatments fail is the neglect of addressing your skin from a holistic viewpoint," said Marci White, Owner of Delete Tattoo Removal & Medical Salon.
  • The Delete Method will be available for patients looking for a fresh start at Delete Tattoo Removal & Medical Salon's Phoenix and Chandler locations.
  • Delete's latest innovation, the Delete Method, a tattoo removal method (patent pending) that provides superior tattoo removal results, faster.

FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis

Retrieved on: 
Tuesday, September 21, 2021
Tablet, Food, Therapy, Miliaria, Rosacea, Irritation, Steroid, Hyperglycemia, Prevalence, BurNIng, Compliance, Itch, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Torso, FDA, Patient, Adolescence, Folliculitis, Body surface area, Scalp, Adult, Allergic contact dermatitis, Doxycycline, Immune system, Hypopigmentation, Glycosuria, Phase, CEO, Telangiectasia, Company, Ageing, Acne, Greasy hair, Dry, Hospira, ASX, Risk, Cushing's syndrome, Perioral dermatitis, Dermatology, Atrophy, Cell, Safety, Infection, Glaucoma, National Psoriasis Foundation, Ulobetasol, HPA, Time, Skin, Pharmaceutical industry, Cosmetics, Generic drug

LEXETTE, a super potent topical corticosteroid,is now approved for the treatment of plaque psoriasis in patients aged 12 years and older.

Key Points: 
  • LEXETTE, a super potent topical corticosteroid,is now approved for the treatment of plaque psoriasis in patients aged 12 years and older.
  • The FDA approved LEXETTE in 2018 based on evidence from two multicentre, randomized, double-blind, vehicle-controlled studies (n=560) in patients with plaque psoriasis involving between 2% to 12% body surface area.
  • LEXETTE (halobetasol propionate) foam is a potent corticosteroid indicated for the topical treatment of plaque psoriasis in patients twelve years of age and older.
  • LEXETTE foam was evaluated for the treatment of moderate to severe plaque psoriasis in two multicentre, randomised, double-blind, vehicle-controlled studies.

Bella Aurora launches its first treatment for white patches on the skin

Retrieved on: 
Tuesday, May 11, 2021
Branches of biology, Biology, Ultraviolet radiation, Melanocyte, Ultraviolet, Human skin color, Hypopigmentation

Approximately two per cent of the global population has this skin condition which, although it is not painful, has a psychological impact."

Key Points: 
  • Approximately two per cent of the global population has this skin condition which, although it is not painful, has a psychological impact."
  • saysDr MatteoBordignon.\nIt was in 2013 that Dr Bordignon published2 his discovery that the MIA protein, produced abnormally by melanocytes, is responsible for hypopigmentation or the formation of white patches on the skin.
  • The treatment must be accompaniedby exposure to natural sunlight or artificial UV light under the supervision of a healthprofessional.
  • It is recommended to follow the treatment for at least six months or until thearea is fully repigmented.\n'

Global Hypopigmentation Disorder Treatment Market Analysis & Trends: Forecast 2018-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 30, 2019
Health, Pharmaceutical, Hypopigmentation

The "Hypopigmentation Disorder Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hypopigmentation Disorder Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026" report has been added to ResearchAndMarkets.com's offering.
  • This report analyzes the current and future scenario of the global hypopigmentation disorder treatment market.
  • The global hypopigmentation disorder treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market.
  • This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global hypopigmentation disorder treatment market.

Hypopigmentation Disorder Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Retrieved on: 
Tuesday, April 16, 2019
Medicine, Clinical medicine, Hypopigmentation, Light therapy, Dermatology, Dermabrasion

LONDON, April 16, 2019 /PRNewswire/ -- Global Hypopigmentation Disorder Treatment Market: Overview

Key Points: 
  • LONDON, April 16, 2019 /PRNewswire/ -- Global Hypopigmentation Disorder Treatment Market: Overview
    This report analyzes the current and future scenario of the global hypopigmentation disorder treatment market.
  • Global Hypopigmentation Disorder Treatment Market: Key Segments
    Based on treatment, the global hypopigmentation disorder treatment market has been segmented into topical drugs, laser therapy, chemical peels, microdermabrasion, and others (phototherapy, etc.).
  • Based on end-user, the global hypopigmentation disorder treatment market has been classified into hospitals, aesthetic clinics & dermatology centers, and others.
  • The global hypopigmentation disorder treatment market has been segmented as below:
    Global Hypopigmentation Disorder Treatment Market, by Treatment

Pigmentation Disorders Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Retrieved on: 
Monday, August 13, 2018
Medicine, Systems biology, Dermatology, Hypopigmentation, Vitiligo, Melasma, Photorejuvenation, Pigmentation disorder

NEW YORK, August 13, 2018 /PRNewswire/ -- Global Pigmentation Disorders Treatment Market: Overview

Key Points: 
  • NEW YORK, August 13, 2018 /PRNewswire/ -- Global Pigmentation Disorders Treatment Market: Overview
    This report analyzes the global pigmentation disorders treatment market in terms of its current and future scenario.Rise in investment in R&D of novel advanced technologies, decrease in social taboos regarding pigmentation, increase in prevalence of pigmentation-related disorders, and rise in awareness about skin rejuvenation and treatment options are likely to drive the expansion of the global market during the forecast period.
  • It also provides market attractiveness analysis in terms of geography and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario prevailing in the global pigmentation disorders treatment market.
  • Global Pigmentation Disorders Treatment Market: Key Segments
    Based on treatment, the global pigmentation disorders treatment market has been segmented into topical drugs, laser therapy, chemical peels, microdermabrasion, phototherapy, and others.In terms of disease indication, the market has been classified into hyperpigmentation (melasma, post-inflammatory hyperpigmentation, solar lentigines, and others) and hypopigmentation (vitiligo, albinism, and others).
  • The global pigmentation disorders treatment market has been segmented as follows: